Changes of number of stock units and votes in Artimplant AB

Changes of number of stock units and votes in Artimplant AB

With reference to Chapter 4, Section 9 of the Swedish Financial Instruments
Trading Act (SFS 1991:980), it is hereby announced that the new issue of Series
B stock units during March 2012 has led to the below changes in the number of
stock units and votes in Artimplant AB.

Before the new issue: Series A stock units 575,000, Series B stock units
117.914.580, total number of stock units 118.489.580 and the number of votes
123.664.580.

Increase due to new issue: Series B stock units 395.492.676.
After the new issue: Series A stock units 575.000, Series B stock units
513.407.256, total number of stock units 513.982.256 and total number of votes
519.157.256.

 
For further information, please contact:

Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 31 746 56 00, +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

 
Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet, for shoulder and other soft
tissue injuries.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on March 30, 2012 at 4 PM (Swedish time).